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objective of optimal surgical treatment. Regression of
left ventricular hypertrophy is a more direct parameter to
quantify the reduced work of the left ventricle and there-
fore to judge the hemodynamic efficiency of the aortic
valve substitute. Recently, biologic stentless aortic
valves have been introduced in the clinical arena be-
cause of their optimal hemodynamic characteristics
reflected by a significantly lower transprosthetic gradi-
ent than that of stented or mechanical valves of the same
size.1,2 Therefore their use appears particularly advanta-
geous in the case of a small aortic anulus.
In a recently published study3 in which we compared
2 groups of patients with aortic stenosis receiving
bileaflet mechanical valves of different sizes, we did
not find a significant difference in the regression of left
ventricular hypertrophy 3 years after the operation. In
the present study we wanted to test the hypothesis that
the better hemodynamic performances of stentless
valves were also reflected by a greater reduction in left
A ortic valve replacement with a prosthetic valve inpatients with aortic stenosis greatly reduces the
afterload of the left ventricle, with consequent better
hemodynamic performance and improved clinical sta-
tus. Residual postoperative gradients are often present
when small-sized prosthetic valves are implanted. The
presence of this residual gradient has been considered to
be the cause of the lack of regression or of the reduced
regression of left ventricular hypertrophy that is the
Objective: Stentless biologic aortic valves are less obstructive than stented
biologic or mechanical valves. Their superior hemodynamic perfor-
mances are expected to reflect in better regression of left ventricular
hypertrophy. We compared the regression of left ventricular hypertro-
phy in 3 groups of patients undergoing aortic valve replacement for
severe aortic stenosis. Group I (10 patients) received stentless biologic
aortic valves, group II (10 patients) received stented biologic aortic
valves, and group III (10 patients) received bileaflet mechanical aortic
valves. Methods: Echocardiographic evaluations were performed before
the operation and after 1 year, and the results were compared with those
of a control group. Left ventricular diameters and function, left ventric-
ular wall thickness, and left ventricular mass were assessed by echocar-
diography. Results: Group I patients had a significantly lower maximum
and mean transprosthetic gradient than the other valve groups (P =
.001). One year after operation there was a significant reduction in left
ventricular mass for all patient groups (P < .01), but mass did not reach
normal values (P = .05). Although the rate of regression in the interven-
tricular septum and posterior wall thickness differed slightly among
groups, their values at follow-up were comparable and still higher than
control values (P = .002). The ratio between interventricular septum and
posterior wall and the ratio between wall thickness and chamber radius
did not change significantly at follow-up. Conclusions: Because the num-
ber of patients was relatively small, we could not use left ventricular
mass regression after 1 year to distinguish among patients undergoing
aortic valve replacement for aortic stenosis by means of valve prosthe-
ses with different hemodynamic performances. (J Thorac Cardiovasc
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ventricular mass when compared with conventional
prosthetic valves. Therefore we analyzed the regression
of hypertrophy in 3 groups of patients who received a
stentless, a stented, or a mechanical valve.
Patients and methods
Patient population. From January 1994 to January 1996,
158 patients underwent isolated aortic valve replacement.
From among them we selected 30 consecutive patients who
fulfilled the following criteria: (1) preoperative echocardio-
graphic evaluation done at our institution; (2) absence of
other associated valvular disease; (3) no history of hyperten-
sion or else mild hypertension well controlled with medical
therapy; (4) normal left ventricular function; (5) no or trivial
aortic regurgitation at follow-up; (6) a diameter between 21
and 23 mm for stented valves. Patients younger than 70 years
received a mechanical valve prosthesis; patients older than 70
years received a biologic valve. The choice between stentless
or stented biologic valves was based on the surgeon’s prefer-
ence. We obtained 3 groups of patients: Ten patients (group I)
received a stentless aortic valve of various sizes (Toronto SPV
[St Jude Medical, Inc, St Paul, Minn] and Sorin stentless
valve [Sorin Biomedica, Saluggia, Italy] with a mean size of
24 ± 3.2).
Ten patients (group II) received a Hancock stented valve
(Hancock Extracorporeal Inc, Anaheim, Calif), size 21 mm (8
cases) or size 23 mm (2 cases). Ten patients (group III)
received a CarboMedics bileaflet mechanical valve (Sulzer
Carbomedics Inc, Austin, Tex), size 21 mm (8 cases) or size
23 mm (2 cases). A fourth group of 10 healthy subjects, with-
out heart disease on routine diagnostic echocardiography and
without a history of systemic hypertension, served as a con-
trol group.
All patients were evaluated before the operation and after a
mean time of 13 ± 6 months for group I, 15 ± 4 months for
group II, and 12 ± 7 months for group III. For patients of
groups I and III, an echocardiographic study was also avail-
able after a mean of 2 years’ follow-up. The time frame of the
study was 15 months. Medical ethics committee approval and
informed patient consent for participation in the study were
obtained in all cases.
Patient characteristics are shown in Table I. Because our
policy is to implant biologic valves after the age of 70 years,
patients receiving bioprostheses were slightly older than both
the patients receiving mechanical valves and the control sub-
jects. Although the difference was not significant, the group
receiving stented bioprostheses contained a higher proportion
of women than did the other groups. All patients had pure
aortic stenosis; however 2 patients in each group had minimal
evidence of aortic regurgitation. None of the patients had
postoperative prosthetic valve insufficiency. Two patients in
the groups receiving biologic valves and 1 patient in the
group receiving mechanical valves had associated coronary
artery disease. The diameter of the implanted prosthesis was
significantly larger for patients receiving stentless valves than
for the other patient groups. Diastolic pressure was an aver-
age of blood pressure as measured before the operation 3
times a day over a period of more than 4 consecutive days.
Three patients in each group were receiving a daily dose of
angiotensin-converting enzyme inhibitors (10 to 20 mg).
Echocardiographic measurements and calculations. At
each follow-up period, M-mode, 2-dimensional, and Doppler
echocardiography were performed with a Hewlett-Packard
series 77025A echocardiograph with a 2.0 to 2.5 MHz trans-
ducer (Hewlett-Packard Company, Andover, Mass). Standard
apical, parasternal, and subcostal views were obtained. The fol-
lowing parameters were measured: left ventricular end-diastolic
and end-systolic diameters; ejection fraction and fractional
shortening; interventricular septum and posterior wall thick-
ness, and maximum and mean flow velocity across the valve.
Then the following parameters were calculated: (1) the
ratio between interventricular septum and posterior wall
thickness; (2) the ratio between left ventricular wall thickness
(interventricular septum plus posterior wall thickness) and
left ventricular chamber radius; (3) the left ventricular mass,
which was calculated from the M-mode measurements by
means of the formula modified by Devereux and Reicher4;
(4) maximum and mean gradient, which were calculated by
means of the modified Bernoulli equation. All values were
indexed for the body surface area.
All parameters were measured and calculated independently
by 2 expert echocardiographers. The echocardiograms were
Table I. Patient characteristics
Group I Group II Group III Control 
(stentless valve) (stented valve) (mechanical valve) (healthy subjects) P value
Age (y) 70.7 ± 3.3 73.6 ± 4.1 64.8 ± 8 61.3 ± 8.2 .01
Sex (M/F) 7/3 3/7 6/4 4/6 NS
BSA (m2) 1.70 ± 0.1 1.69 ± 0.1 1.70 ± 0.1 1.71 ± 0.1 NS
Associated AI 2 2 2 — NS
Valve size (mm) 24.1 ± 3.2* 21.4 ± 0.9 21.4 ± 0.9 — .02
Anulus diameter/BSA 1.36 ± 0.1 1.27 ± 0.1 1.25 ± 0.1 — NS
Diastolic blood pressure (mm Hg) 71.8 ± 8.7 70 ± 6.2 72 ± 10.4 73 ± 8.2 NS
Maximum gradient preop (mm Hg) 88.2 ± 28 101.2 ± 32 85.2 ± 30 — NS
BSA, Body surface area; AI, aortic insufficiency; NS, not significant.
*Significantly different from groups II and III.
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reviewed by a third investigator if the first 2 investigators
were not in agreement.
Statistical analysis. Two-factor repeated-measures analy-
sis of variance with repeated measures on 1 factor was used
to compare echocardiographic parameters in the 4 groups of
patients. When significant differences were detected, pair-
wise comparisons were made by the Scheffé F test.
Comparisons of the remaining continuous or discrete vari-
ables among groups were performed by means of an unpaired
Student t test or a c 2 test, respectively (SPSS for Windows
Software, SPSS, Inc, Chicago, Ill). Data are expressed as
mean ± 1 standard deviation unless otherwise indicated.
Results
At follow-up all patients had an improvement in
functional class. The majority of patients (23/30, 77%)
were in New York Heart Association (NYHA) class I.
Three patients in group II and 2 patients each in the
other groups were in NYHA class II.
Preoperatively, left ventricular diameters and func-
tion were comparable among study groups and not sig-
nificantly different from the control group. At follow-
up, all values changed slightly, remaining within the
normal range (Table II).
As expected from their known optimal hemodynamic
performances, stentless bioprostheses assured a signifi-
cantly lower maximum and mean transprosthetic gradi-
ent that was independent of the size of the prosthesis
implanted (P = .001) (Table II). One year after operation
left ventricular mass index was significantly reduced (P
< .01) for all patient groups, but it was still different
from control values (P = .05). There were no significant
differences in the rate of regression in left ventricular
mass among the 3 groups of patients (Fig 1).
Group I patients (stentless valves) had a significant
reduction in the interventricular septum (P = .03) and
posterior wall (P = .04) thickness; group II patients
(stented valve) had a significant reduction in the inter-
ventricular septum only (P = .01); group III patients
(mechanical valves) had a significant reduction in the
posterior wall (P = .04) and in the interventricular sep-
tum thickness, although in the latter it reached border-
line statistical significance (P = .06) (Table III).
Although the rate of regression in the interventricu-
lar septum and posterior wall thickness appeared to be
slightly different among patient groups, at follow-up
there were no significant differences among the 3
groups in the ventricular wall thickness. Similar values
were reached in the 3 groups, and they were still sig-
nificantly higher than control values (P < .003) (Fig 2).
The ratio between interventricular septum and poste-
rior wall and the ratio between left ventricular wall
thickness and chamber radius (Fig 3) did not change
significantly at follow-up and in all patient groups
remained significantly different from control values.
Left ventricular mass index at 2 years in groups I
(stentless valves) and III (mechanical valves) did not
change significantly (137 ± 33 g/m2 and 136 ± 35 g/m2;
P = NS vs values at 1 year of follow-up, respectively).
Discussion
Stentless aortic valve prostheses have demonstrated
better hemodynamic performances than stented biolog-
ic and mechanical valve prostheses.2,5 Because of their
peculiar anatomic features, their hemodynamic charac-
teristics appear to be similar to those of homograft
valves. These optimized hemodynamic characteristics
should result in a more complete regression of left ven-
tricular hypertrophy, which is known to be associated
with cardiovascular morbidity and mortality.6 Even
Table II. Left ventricular diameters, left ventricular function, and mean gradient for patients receiving stentless
bioprostheses (group I), stented bioprostheses (group II), and mechanical valves (group III) and for control subjects
Echocardiographic parameters
LVEDDi LVESDi EF FS Maximum gradient Mean gradient 
(mm/m2) (mm/m2) (%) (%) (mm Hg) (mm Hg)
Group I
Preoperative 28.8 ± 4.1 18.4 ± 4.5 67 ± 10 36 ± 10 88.2 ± 28 57.7 ± 20.4
Follow-up 26 ± 3.3 16.1 ± 2.8 68 ± 11 37 ± 9 15.1 ± 7.5* 7.9 ± 4*
Group II
Preoperative 28.3 ± 4.7 18.4 ± 5.7 63 ± 12 34 ± 10 101.2 ± 32 61.1 ± 18.2
Follow-up 26 ± 3.6 16.3 ± 4.7 64 ± 11 35 ± 9 34.6 ± 12.6 18.2 ± 4.6
Group III
Preoperative 29.4 ± 2 18.4 ± 1.9 65 ± 7 36 ± 6 85.2 ± 30 52 ± 22.4
Follow-up 27 ± 3 17.9 ± 2.4 61 ± 8 33 ± 6 29.5 ± 8.9 15.7 ± 3.8
Control 28.8 ± 2.7 18.9 ± 2.7 62 ± 10 34 ± 7 — —
LVEDDi, Left ventricular end-diastolic diameter index; LVESDi, left ventricular end-systolic diameter index; EF, ejection fraction; FS, fractional shortening.
*P = .001 versus groups II and III.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 4
De Paulis et al   593
moderate left ventricular hypertrophy can often be the
cause of arrhythmias, congestive heart failure, or sudden
death.7 Therefore the extent and rate of regression in left
ventricular hypertrophy after aortic valve replacement
has been considered an important determinant of long-
term survival. The beneficial effects of a less obstructive
valve have often been demonstrated, considering
together patients with aortic stenosis and aortic insuffi-
ciency, as well as patients with good or depressed ven-
tricular function. In this study we selected a group of
patients with pure aortic stenosis and normal ventricular
function in whom we thought it easier to observe and
quantify the beneficial effect of an optimal reduction of
afterload. Although patients with impaired ventricular
function might receive greater clinical benefit from a
minimal or absent transprosthetic gradient, regression in
their left ventricular mass index would have been diffi-
cult to compare with that of patients with normal ven-
Fig 1. Mean values (± standard error of the mean) of left ventricular mass index in patients with stentless bio-
prostheses, stented bioprostheses, and mechanical prostheses referenced against the control group before the
operation and at postoperative follow-up. A significant reduction in left ventricular mass is present for all groups
of patients although it remained above the normal values. *P = .0001 vs control; **P = 0.05 vs control.
Table III. Left ventricular mass index, interventricular septum and posterior wall thickness, their ratio, and the ratio
between left ventricular wall thickness and radius for patients receiving stentless bioprostheses (group I), stented
bioprostheses (group II), and mechanical valves (group III) and for control subjects
Echocardiographic parameters
LV mass index IVS PW 
(g/m2) (mm) (mm) IVS/PW Th/r
Group I
Preoperative 198 ± 45 15.5 ± 2.4 13.1 ± 1.1 1.20 ± 0.1 0.57 ± 0.13
Follow-up 135 ± 32 13.2 ± 1.8 12.1 ± 1.3 1.12 ± 0.1 0.58 ± 0.1
Group II
Preoperative 185 ± 56 14.6 ± 2.7 12.2 ± 1.3 1.22 ± 0.2 0.57 ± 0.12
Follow-up 144 ± 37 12.7 ± 2.2 12.2 ± 2.2 1.05 ± 0.1 0.59 ± 0.1
Group III
Preoperative 216 ± 36 15 ± 2.1 13.4 ± 2.5 1.16 ± 0.3 0.57 ± 0.1
Follow-up 139 ± 31 12.7 ± 2.1 10.8 ± 1.7 1.17 ± 0.2 0.51 ± 0.1
Control 107 ± 17 9.4 ± 1.1 9.1 ± 1.1 1.04 ± 0.1 0.37 ± 0.05
LV, Left ventricle; IVS, interventricular septum; PW, posterior wall; Th/r, ratio between left ventricular thickness and radius (P values are indicated in Figs 1 to 3).
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tricular function. We found that all patients operated on
for aortic stenosis had a significant reduction in left ven-
tricular mass irrespective of the type of valve substitute.
The reduction of the afterload after valve replacement
was sufficient to cause in all patients a similar reduction
of the left ventricular hypertrophy to a certain point,
after which it decreased to a slower rate. We were
expecting a much greater reduction in left ventricular
mass in patients with stentless valves, especially because
we had selected patients with relatively small-diameter
biologic stented or mechanical valves. Patients with stent-
less valves showed a 32% reduction in left ventricular
Fig 2. Mean values (± standard error of the mean) of interventricular septum (A) and left ventricular posterior wall thick-
ness (B) in patients with stentless bioprostheses, stented bioprostheses, and mechanical prostheses referenced against the
control group before the operation and at postoperative follow-up. A significant reduction in interventricular septum thick-
ness is evident for all groups of patients, but at follow-up it was still significantly different from control values (A).
Posterior wall thickness decreased significantly in group I and group III patients only, but in all groups it remained sig-
nificantly higher than control values (B). *P = .0001 vs control; **P = .0021 vs control.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 4
De Paulis et al   595
hypertrophy, compared with 28% for patients with
stented biologic valves and 36% for patients with
mechanical valves. Although at follow-up stentless
valves showed a symmetric reduction in the left ventric-
ular wall thickness that was more evident in the inter-
ventricular septum for stented biologic valves and in the
posterior wall for mechanical valves, their final values
were comparable and still higher than control values.
Very recently, many studies have shown a greater
regression in left ventricular mass after aortic valve
replacement with stentless valves than with classic
valve substitutes.8,9 Christakis and associates10 did not
find that the type of prosthesis could influence the
extent of mass regression in the early postoperative
period.10 However, the same group reported an opti-
mized mass regression with stentless valves after 1 year
of follow-up.11 Jin and colleagues,12 who evaluated the
regression of left ventricular hypertrophy in a large
number of patients after aortic valve replacement with
different types of valve substitutes, showed that the
patient with a stentless or homograft valve had a greater
reduction in the left ventricular mass than the patient
who received a stented biologic or mechanical valve.
After a follow-up period of more than 3 years, they
reported a left ventricular mass index of 145 g/m2 for
all patients with aortic stenosis and 144 g/m2 for
patients with a stentless valve. Similarly, Gonzalez-
Juanatey and associates,13 who observed the changes in
left ventricular mass in a group of patients with differ-
ent sizes of biologic or mechanical valves, demonstrat-
ed a more complete regression in left ventricular hyper-
trophy in patients with larger valves. The left ventricu-
lar mass index was 137 g/m2 for patients receiving 19
mm aortic prostheses and 124 g/m2 for those receiving
25 mm aortic prostheses, with a rate of reduction of
about 10% and 28%, respectively. However, although
both studies demonstrated a greater reduction in left
ventricular mass index in patients with lower transpros-
thetic gradients (homograft valve in 1 case and larger
biologic or mechanical valve in the second case), the
postoperative values in left ventricular mass and the
rate of reduction from preoperative levels were similar
to ours and still different from control values. Sim and
associates,14 who also demonstrated, after a follow-up
period of 3 years, a less-pronounced reduction in left
ventricular mass in patients with 19 mm stented or
mechanical valves compared with similar valves of
larger diameters, reported a postoperative mass index
of 120 g/m2 (with a preoperative value of only 129
g/m2) that was not different from the postoperative
mass index of patients with larger valves (ie, 125 g/m2
for patients receiving 25 mm aortic prostheses).
Finally, Lund and coworkers15 recently analyzed the
impact of size mismatch in a group of patients operat-
ed on for aortic stenosis with different sizes of St Jude
Medical valves. After a mean period of 18 months their
left ventricular mass index was 153 ± 53 g/m2 with a
posterior wall thickness of 12 ± 2 mm. Noteworthy,
they found that small valve orifice diameter and valve
prosthesis size mismatch (along with left ventricular
Fig. 3. Mean values (± standard error of the mean) of left ventricular wall thickness/chamber radius ratio (Th/r)
in patients with stentless bioprostheses, stented bioprostheses, and mechanical prostheses referenced against the
control group before the operation and at postoperative follow-up. There were no significant differences between
the preoperative and postoperative results.
end-diastolic dimension and impaired left ventricular
function) were independent determinants of Doppler
gradients. Most interestingly, they did not find a corre-
lation between the 18-month gradient and the left ven-
tricular mass index or the rate of reduction in the left
ventricular mass index from the preoperative level.
These results led them to the conclusion that the incom-
plete hypertrophy regression could not be ascribed to
the relatively obstructive mechanical prostheses.
There are several reasons why regression of left ven-
tricular hypertrophy is incomplete after aortic valve
replacement for aortic stenosis. First, the left ventricu-
lar myocardial collagen fibrosis especially in the inter-
ventricular septum might take a much longer time to
return to normal or the myocardial structural abnor-
mality might never regress in patients with truly patho-
logic hypertrophy.16 Second, other host-related factors
should be taken into consideration. Age is known to be
an independent factor of left ventricular hypertrophy.17
Lindroos and associates,18 who evaluated the amount
of left ventricular hypertrophy in an old patient popu-
lation, found that the increase of left ventricular mass is
due partly to age-related disease but also partly to an
independent effect of age. The left ventricular mass
was often found to exceed 70% of the standard limits in
the oldest patient cohort (85 years old). Although our
patients receiving mechanical valves or control valves
were slightly younger than patients receiving biologic
valves, the differences seem too small to justify an age-
dependent difference in left ventricular mass index.
Gender should also be considered, because left ventric-
ular mass, when indexed either for body surface area or
height, has been found to be greater in men than
women.19 However, female patients show a greater
increase in left ventricular mass with advanced age,
apparently because of the higher incidence of obesity
in elderly women. Therefore it is unlikely that the high
proportion of women in the group receiving stented
biologic valves could have influenced the differences in
left ventricular mass regression among our patient
groups. Hypertension that is often present in an elderly
patient population might significantly influence the
rate of regression of left ventricular hypertrophy. In our
study we excluded patients with evidence of hyperten-
sion, but we cannot rule out that patients with a blunted
nocturnal fall in blood pressure might have an in-
creased left ventricular mass. However, Verdecchia and
coworkers20 demonstrated that, at least in hypertensive
men, daytime hypertension was a sufficient determi-
nant of left ventricular wall thickening independent of
the presence or absence of a nocturnal fall in blood
pressure. Finally, the classic index of left ventricular
mass for body surface area might be inappropriate.
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Lauer and associates21 recently suggested a new
method of indexing, independent of obesity, that might
reduce the variability associated with body size and
gender.
All these considerations indicate that in an elderly
population (ie, those most likely to receive a biopros-
thesis) with reduced physical activity who often have
hypertension and have had aortic stenosis for a great
number of years, it might be difficult to observe a com-
plete regression of left ventricular mass and to ascribe
it to the type of valve substitute. Conversely, differ-
ences in the rate of regression of left ventricular hyper-
trophy could be easier to detect in a young patient pop-
ulation with a greater increase in cardiac output during
daily activity. It is also possible that other parameters
rather than the simple assessment of left ventricular
mass could be more sensitive markers of the beneficial
effects of an optimal reduction of ventricular pressure
load. Noteworthy, Jin and colleagues12 showed that
patients with less obstructive valve prostheses (homo-
graft or stentless biologic valves) had a substantially
greater increase in the rates of dimensional shortening
and wall thickening than patients with stented valve
prostheses. They22 had also previously shown that an
early decrease in peak systolic stress was 50% greater
after aortic valve replacement with a stentless valve
than with a stented one. Additionally or alternatively to
these more sensitive parameters, a more appropriate
index could better help in distinguishing differences in
left ventricular hypertrophy between patients with dif-
ferent valve substitutes.
One year of follow-up appears to be sufficient to
assess the regression of left ventricular hypertrophy in
patients undergoing aortic valve replacement. Jin and
associates12 found no differences in left ventricular
mass or in left ventricular structure and function
between 6 months and 3 years of follow-up. We also
demonstrated in a group of patients operated on for
aortic stenosis with different sizes of mechanical valves
that the left ventricular mass index was not different
between 1 year and 3 years of follow-up.3 Similarly, in
2 groups of patients of the present study (group I and
group III) in whom a longer follow-up of 2 years was
also available, no changes in left ventricular mass index
were present. Monrad and coworkers23 had already
clearly demonstrated that the regression of left ventric-
ular hypertrophy is maximal within the first year of fol-
low-up and that more than 8 years are necessary to
detect a further reduction of ventricular mass. They
considered only patients with different types of stented
biologic or mechanical valves; therefore we cannot
exclude the possibility that stentless valves or homo-
grafts will behave differently. Del Rizzo and col-
We thank A. Parma, MD, MSc, for his assistance in the sta-
tistical analysis of our data.
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leagues,11 after a careful follow-up of the Toronto SPV
stentless valve, reported a progressive decrease in left
ventricular mass index within the first year of follow-
up but no differences in left ventricular mass regression
between 1 year and 3 years of follow-up.
It is intuitive that an aortic valve prostheses with opti-
mized hemodynamic performance and minimal or no
residual postoperative gradient should result in better
ventricular structure and function. In this study the sim-
ple assessment of left ventricular hypertrophy did not
discriminate between patients with different types of
valves after an intermediate period of follow-up.
However, even when the beneficial effect of stentless
valves on left ventricular mass regression becomes
clear, it will be necessary to demonstrate that the incom-
plete regression of left ventricular mass after aortic
valve replacement is sufficient to determine differences
in clinical status or in overall survival. Large clinical tri-
als comparing survival and cardiac related events with-
in patients with stented and stentless valves are there-
fore warranted.
Limitations of the study. The major limitation of
this study is the fact that patients were not randomized
to receive a different type of valve prosthesis. Although
selection criteria were very strict and most of the clini-
cal variables were not different between the population
groups, many other factors that could conceivably con-
tribute to differences might not have been included.
Selection bias often can be difficult to describe. How-
ever, inasmuch as the result of this study was different
from what we were expecting, the possibility of selec-
tion bias may be attenuated. Our control patients were
slightly younger than those in the study groups and
might not have been an accurate basis for comparison,
especially for patients receiving biologic implants.
Nevertheless, control values are easily available in the
literature. Finally, the relatively small group of patients
considered indicates a low statistical power of the
study. On the basis of the data on left ventricular mass
regression available in the literature, and to identify a
25% decrease in left ventricular mass, a larger number
of patients was necessary. Although, the statistical
power of the study calculated from our data appears to
be sufficiently high (from 87% to 95% for pairwise
comparisons, at an a level of .05) it carries a strong b
error. Obviously, a larger number of patients would
have strengthened the results and improved the study.
The strict selection of patients and the accuracy of fol-
low-up has prevented us from concluding a larger study
in a relatively short period of time. However, we think
that the information obtained from this study is suffi-
cient to show the need of a large randomized trial com-
paring different valve substitutes.
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